| Accession |
PRJCA017235 |
| Title |
SHR-1210-II-217 A Phase II study of PD-L1 combined with FMTN versus PD-L1 monotherapy or investigator-selected chemotherapy in the treatment of recurrent metastatic cervical cancer |
| Relevance |
Medical |
| Data types |
biomarker,gene,protein,metabolic data,etc
|
| Organisms |
Homo sapiens
|
| Description |
This is a randomized, open, controlled, multicenter phase II study to evaluate the efficacy and safety of carrilizumab in combination with Famitinib malate versus carrilizumab alone or investigator-selected chemotherapy in patients with recurrent metastatic cervical cancer who have failed prior treatment with platinum-containing regimen. The primary study endpoint was ORR Group A vs. Group B, BICR based on RECIST v1.1 criteria). |
| Sample scope |
Multiisolate |
| Release date |
2023-06-02 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
NA
|
NA
|
|
|
|
| Submitter |
luchongyang
chongyang
lu (chongyang.lu@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-05-24 |
